The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

被引：0
|
作者：
Yu, Guopan [1 ]
Yao, Zurong [1 ]
Yin, Zhao [1 ]
Zhang, Yu [1 ]
Zhao, Weihua [2 ]
Weng, Guangyang [3 ]
Guo, Ziwen [4 ]
Sun, Zhiqiang [5 ]
Shi, Pengcheng [1 ]
Jiang, Xuejie [6 ]
Xu, Dan [1 ]
Xuan, Li [1 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China
[3] Shenzhen Second Peoples Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[5] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 2, Dept Hematol, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
homoharringtonine; venetoclax/azacitidine; acute myeloid leukemia; efficacy; safety;
D O I：
10.1182/blood-2024-206872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4283 / 4283
页数：1
相关论文
共 50 条
  • [41] Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features
    Gutman, Jonathan A.
    Winters, Amanda
    Amaya, Maria L.
    McMahon, Christine M.
    Schowinsky, Jeffrey
    Abbott, Diana
    Hammes, Andrew
    Pei, Shanshan
    Stevens, Brett M.
    Jordan, Craig T.
    Smith, Clayton
    Pollyea, Daniel A.
    BLOOD, 2020, 136
  • [42] Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
    Gojo, Ivana
    Stuart, Robert K.
    Webster, Jonathan
    Blackford, Amanda
    Varela, Juan Carlos
    Morrow, Jillian
    DeZern, Amy E.
    Foster, Matthew C.
    Levis, Mark J.
    Coombs, Catherine C.
    Prince, Gabrielle T.
    Smith, B. Douglas
    Van Deventer, Hendrik W.
    Jamieson, Katarzyna
    Varadhan, Ravi
    Vincent, Benjamin G.
    Serody, Jonathan S.
    Luznik, Leo
    Zeidner, Joshua F.
    BLOOD, 2019, 134
  • [43] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    Kadia, Tapan M.
    Reville, Patrick K.
    Wang, Xuemei
    Rausch, Caitlin R.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval G. G.
    DiNardo, Courtney D. D.
    Sasaki, Koji
    Issa, Ghayas C. C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J. J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N. N.
    Jabbour, Elias
    Takahashi, Koichi
    Malla, Rashmi
    Quagliato, Kelly
    Kanagal-Shamanna, Rashmi
    Popat, Uday R. R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina Y. Y.
    Ravandi, Farhad
    Kantarjian, Hagop M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +
  • [44] Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
    Stempel, Jessica M.
    Uy, Geoffrey L.
    Dinner, Shira N.
    Gojo, Ivana
    Reed, Daniel
    Roy, Rupali
    Byrd, Kenneth P.
    Yerrabothala, Swaroopa
    Lai, Catherine E.
    Doucette, Kimberley
    Caldwell, Anne
    Blaha, Ondrej
    Podoltsev, Nikolai A.
    Mendez, Lourdes M.
    Bewersdorf, Jan Philipp
    Kewan, Tariq
    Wistuba, Ignacio
    Alatrash, Gheath
    Haymaker, Cara L.
    Streicher, Howard
    Sharon, Elad
    Mph, Richard Little M. D.
    Gore, Steven D.
    Radich, Jerald P.
    Mdphd, Brent L. Wood
    Zeidan, Amer M.
    Shallis, Rory M.
    BLOOD, 2024, 144 : 737 - 738
  • [45] Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
    Richard-Carpentier, Guillaume
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [46] Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia
    Winters, Amanda C.
    Maloney, Kelly W.
    Treece, Amy L.
    Gore, Lia
    Franklin, Anna K.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (10)
  • [47] Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
    Manda, Sudhir
    Anz, Bertrand Marquess
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte Aragaw
    Melear, Jason M.
    Cruz, Jose C.
    Fanning, Suzanne
    Sharman, Jeff Porter
    Kang, Kingston
    Svensson, Anders
    Pai, Madhavi
    Geils, George F.
    Renshaw, John Scott
    Donnellan, William Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience
    Yu, Wen-Jing
    Jia, Jinsong
    Wang, Jing
    Tang, Fei-Fei
    Gong, Lizhong
    Liu, Xiaohong
    Zhu, Xiaolu
    Zhao, Xiaosu
    Huang, Xiao Jun
    Jiang, Hao
    BLOOD, 2021, 138
  • [49] Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
    De Botton, Stephane
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Riva, Marta
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Hui, Jianan
    Gianolio, Diego A.
    Patel, Prapti Arvind
    Recher, Christian
    Dohner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study
    Yang, Li
    Chen, Fangli
    Liang, Hong
    Bai, Yunsong
    Wu, Wenzhong
    Yan, Xiaojing
    Ren, Jinhai
    Li, Si
    Yu, Yang
    Tong, Laigen
    Pan, Deng
    Liu, Ligen
    BLOOD, 2023, 142
12345